A Risk-Benefit Assessment of Dementia Medications: Systematic Review of the Evidence

Atrophy of the cholinergic basal forebrain in dementia with Lewy bodies and Alzheimer’s disease dementia

(2014) Michel J. Grothe et al.   JOURNAL OF NEUROLOGY

Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis

(2014) H.-F. Wang et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Representation of older patients in clinical trials for drug approval in Japan

(2014) Yasuko Asahina et al.   Journal of Nutrition Health & Aging

The effect of funding sources on donepezil randomised controlled trial outcome: a meta-analysis

(2014) Lewis O J Killin et al.   BMJ Open

The worldwide economic impact of dementia 2010

(2013) Anders Wimo et al.   Alzheimers & Dementia

The global prevalence of dementia: A systematic review and metaanalysis

(2013) Martin Prince et al.   Alzheimers & Dementia

Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia: Evidence Review for a Clinical Practice Guideline

(2013) Parminder Raina et al.   ANNALS OF INTERNAL MEDICINE

Current Pharmacologic Treatment of Dementia: A Clinical Practice Guideline from the American College of Physicians and the American Academy of Family Physicians

(2013) Amir Qaseem   ANNALS OF INTERNAL MEDICINE

Treatment for mild cognitive impairment: systematic review

(2013) Claudia Cooper et al.   BRITISH JOURNAL OF PSYCHIATRY

Efficacy and safety of cognitive enhancers for patients with mild cognitive impairment: a systematic review and meta-analysis

(2013) A. C. Tricco et al.   CANADIAN MEDICAL ASSOCIATION JOURNAL

Reliability of the Alzheimer’s Disease Assessment Scale (ADAS-Cog) in longitudinal Studies

(2013) Anzalee Khan et al.   Current Alzheimer Research

Efficacy of Memantine, Donepezil, or Their Association in Moderate-Severe Alzheimer’s Disease: A Review of Clinical Trials

(2013) Ivana Molino et al.   TheScientificWorldJOURNAL

The Alzheimer’s Disease Assessment Scale-Cognitive-Plus (ADAS-Cog-Plus): an expansion of the ADAS-Cog to improve responsiveness in MCI

(2012) Jeannine Skinner et al.   Brain Imaging and Behavior

Alzheimer's disease, β-amyloid, glutamate, NMDA receptors and memantine - searching for the connections

(2012) Wojciech Danysz et al.   BRITISH JOURNAL OF PHARMACOLOGY

Acetylcholinesterase inhibitors and the risk of hip fracture in Alzheimer's disease patients: A case-control study

(2012) Iskandar Tamimi et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Assessment scales in dementia

(2012) Bart Sheehan   Therapeutic Advances in Neurological Disorders

Lack of Evidence for the Efficacy of Memantine in Mild Alzheimer Disease

(2011) Lon S. Schneider   ARCHIVES OF NEUROLOGY

Detection of early Alzheimer's disease in MCI patients by the combination of MMSE and an episodic memory test

(2011) Ana Pozueta et al.   BMC Neurology

Glutamate NMDA receptor dysregulation in Parkinson’s disease with dyskinesias

(2011) Imtiaz Ahmed et al.   BRAIN

Dementia Medications and Risk of Falls, Syncope, and Related Adverse Events: Meta-Analysis of Randomized Controlled Trials

(2011) Dae Hyun Kim et al.   JOURNAL OF THE AMERICAN GERIATRICS SOCIETY

The basal forebrain cholinergic system in aging and dementia. Rescuing cholinergic neurons from neurotoxic amyloid-β42 with memantine

(2010) Csaba Nyakas et al.   BEHAVIOURAL BRAIN RESEARCH

The cholinergic system and Parkinson disease

(2010) Nicolaas I. Bohnen et al.   BEHAVIOURAL BRAIN RESEARCH

Potential Cardiotoxic Reaction Involving Rivastigmine and Beta-Blockers: A Case Report and Review of the Literature

(2010) Barbara Paulison et al.   Cardiovascular Toxicology

Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psychopharmacology

(2010) John T O’Brien et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial

(2010) Murat Emre et al.   LANCET NEUROLOGY

Effects of a central cholinesterase inhibitor on reducing falls in Parkinson disease

(2010) K. A. Chung et al.   NEUROLOGY

Review of Alzheimer's disease scales: is there a need for a new multi-domain scale for therapy evaluation in medical practice?

(2010) Philippe Robert et al.   Alzheimers Research & Therapy

Current Alzheimer's disease clinical trials: Methods and placebo outcomes

(2009) Lon S. Schneider et al.   Alzheimers & Dementia

Safety and Tolerability of Donepezil in Mild Cognitive Impairment: Open-Label Extension Study

(2009) Rachelle S. Doody et al.   American Journal of Alzheimers Disease and Other Dementias

Syncope and Its Consequences in Patients With Dementia Receiving Cholinesterase Inhibitors

(2009) Sudeep S. Gill et al.   ARCHIVES OF INTERNAL MEDICINE

Factors Associated with Serious Adverse Reactions to Cholinesterase Inhibitors

(2009) Antoine Pariente et al.   CNS DRUGS

Long-term treatment of patients with Alzheimer's disease in primary and secondary care: results from an international survey

(2009) Lutz Froelich et al.   CURRENT MEDICAL RESEARCH AND OPINION

Diagnosis and Treatment of Patients with Severe Alzheimer’s Disease

(2009) Thierry Voisin et al.   DRUGS & AGING

Cholinesterase Inhibitor and N-Methyl-D-Aspartic Acid Receptor Antagonist Use in Older Adults with End-Stage Dementia: A Survey of Hospice Medical Directors

(2009) Joseph W. Shega et al.   JOURNAL OF PALLIATIVE MEDICINE

Cholinesterase Inhibitors and Incidence of Bradycardia in Patients with Dementia in the Veterans Affairs New England Healthcare System

(2009) Rohini K. Hernandez et al.   JOURNAL OF THE AMERICAN GERIATRICS SOCIETY

Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial

(2009) Dag Aarsland et al.   LANCET NEUROLOGY

Randomized controlled trial of memantine in dementia associated with Parkinson's disease

(2009) Iracema Leroi et al.   MOVEMENT DISORDERS

Donepezil delays progression to AD in MCI subjects with depressive symptoms

(2009) P. H. Lu et al.   NEUROLOGY

Cholinesterase Inhibitors and Hospitalization for Bradycardia: A Population-Based Study

(2009) Laura Y. Park-Wyllie et al.   PLOS MEDICINE

Pathophysiology of vascular dementia

(2009) Francesco Iemolo et al.   Immunity & Ageing

Detecting Dementia With the Mini-Mental State Examination in Highly Educated Individuals

(2008) Sid E. O’Bryant et al.   ARCHIVES OF NEUROLOGY

Diagnosis and treatment of dementia: 3. Mild cognitive impairment and cognitive impairment without dementia

(2008) H. Chertkow et al.   CANADIAN MEDICAL ASSOCIATION JOURNAL

Donepezil Treatment of Patients with Severe Alzheimer’s Disease in a Japanese Population: Results from a 24-Week, Double-Blind, Placebo-Controlled, Randomized Trial

(2008) Akira Homma et al.   DEMENTIA AND GERIATRIC COGNITIVE DISORDERS

Published randomized controlled trials of drug therapy for dementia often lack complete data on harm

(2008) P.E. Lee et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Results, Rhetoric, and Randomized Trials: The Case of Donepezil

(2008) John R. Gilstad et al.   JOURNAL OF THE AMERICAN GERIATRICS SOCIETY

Safety and efficacy of galantamine (Reminyl) in severe Alzheimer's disease (the SERAD study): a randomised, placebo-controlled, double-blind trial

(2008) Alistair Burns et al.   LANCET NEUROLOGY

Safety and efficacy of galantamine in subjects with mild cognitive impairment

(2008) B. Winblad et al.   NEUROLOGY